JP2016505556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505556A5 JP2016505556A5 JP2015545935A JP2015545935A JP2016505556A5 JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5 JP 2015545935 A JP2015545935 A JP 2015545935A JP 2015545935 A JP2015545935 A JP 2015545935A JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 148
- 239000012634 fragment Substances 0.000 claims description 103
- 239000000427 antigen Substances 0.000 claims description 97
- 102000036639 antigens Human genes 0.000 claims description 97
- 108091007433 antigens Proteins 0.000 claims description 97
- 238000006467 substitution reaction Methods 0.000 claims description 44
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 41
- 102000057977 human CLEC4C Human genes 0.000 claims description 23
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 17
- 108010014726 Interferon Type I Proteins 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 102000002227 Interferon Type I Human genes 0.000 claims description 11
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 241000282560 Macaca mulatta Species 0.000 claims description 4
- 102000002689 Toll-like receptor Human genes 0.000 claims description 4
- 108020000411 Toll-like receptor Proteins 0.000 claims description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 208000012263 renal involvement Diseases 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000034994 death Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 26
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 20
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 20
- 238000000034 method Methods 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 4
- 102000001326 Chemokine CCL4 Human genes 0.000 description 4
- 108010055165 Chemokine CCL4 Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 4
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 4
- 108010018844 interferon type III Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019034198A JP6889741B2 (ja) | 2012-12-10 | 2019-02-27 | 抗血液樹状細胞抗原２抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735362P | 2012-12-10 | 2012-12-10 | |
| US61/735,362 | 2012-12-10 | ||
| US201361763270P | 2013-02-11 | 2013-02-11 | |
| US61/763,270 | 2013-02-11 | ||
| PCT/US2013/074208 WO2014093396A1 (en) | 2012-12-10 | 2013-12-10 | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034198A Division JP6889741B2 (ja) | 2012-12-10 | 2019-02-27 | 抗血液樹状細胞抗原２抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505556A JP2016505556A (ja) | 2016-02-25 |
| JP2016505556A5 true JP2016505556A5 (enExample) | 2017-01-26 |
| JP6490591B2 JP6490591B2 (ja) | 2019-03-27 |
Family
ID=49883267
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545935A Active JP6490591B2 (ja) | 2012-12-10 | 2013-12-10 | 抗血液樹状細胞抗原２抗体およびその使用 |
| JP2019034198A Active JP6889741B2 (ja) | 2012-12-10 | 2019-02-27 | 抗血液樹状細胞抗原２抗体およびその使用 |
| JP2021086053A Pending JP2021130677A (ja) | 2012-12-10 | 2021-05-21 | 抗血液樹状細胞抗原２抗体およびその使用 |
| JP2024006009A Pending JP2024045253A (ja) | 2012-12-10 | 2024-01-18 | 抗血液樹状細胞抗原２抗体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034198A Active JP6889741B2 (ja) | 2012-12-10 | 2019-02-27 | 抗血液樹状細胞抗原２抗体およびその使用 |
| JP2021086053A Pending JP2021130677A (ja) | 2012-12-10 | 2021-05-21 | 抗血液樹状細胞抗原２抗体およびその使用 |
| JP2024006009A Pending JP2024045253A (ja) | 2012-12-10 | 2024-01-18 | 抗血液樹状細胞抗原２抗体およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9902775B2 (enExample) |
| EP (2) | EP3686218A1 (enExample) |
| JP (4) | JP6490591B2 (enExample) |
| KR (2) | KR20150094658A (enExample) |
| CN (2) | CN105452295B (enExample) |
| AU (1) | AU2013359419B2 (enExample) |
| BR (1) | BR122020023058B1 (enExample) |
| CA (1) | CA2893375A1 (enExample) |
| CY (1) | CY1122956T1 (enExample) |
| DK (1) | DK2928923T3 (enExample) |
| EA (1) | EA034757B1 (enExample) |
| ES (1) | ES2780398T3 (enExample) |
| HR (1) | HRP20200174T1 (enExample) |
| HU (1) | HUE047874T2 (enExample) |
| IL (2) | IL238804B (enExample) |
| LT (1) | LT2928923T (enExample) |
| MX (1) | MX363407B (enExample) |
| NZ (1) | NZ708033A (enExample) |
| PL (1) | PL2928923T3 (enExample) |
| PT (1) | PT2928923T (enExample) |
| RS (1) | RS60084B1 (enExample) |
| SI (1) | SI2928923T1 (enExample) |
| SM (1) | SMT202000193T1 (enExample) |
| WO (1) | WO2014093396A1 (enExample) |
| ZA (1) | ZA201503881B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2968561B1 (fr) † | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
| WO2015095143A1 (en) | 2013-12-16 | 2015-06-25 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
| MX2016008520A (es) * | 2013-12-24 | 2016-11-30 | Astellas Pharma Inc | Anticuerpo bdca-2 antihumano novedoso. |
| FR3034420A1 (fr) * | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
| FR3045386B1 (fr) | 2015-12-16 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire |
| EP3448425A1 (en) * | 2016-04-28 | 2019-03-06 | Biogen MA Inc. | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
| CN110129298B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 一种磷脂酶d突变体及其应用 |
| US11634495B2 (en) | 2017-04-07 | 2023-04-25 | Miltenyi Biotec B.V. & Co. KG | Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303) |
| WO2019210034A1 (en) * | 2018-04-27 | 2019-10-31 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
| CN119080931A (zh) * | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| EP3890773A4 (en) * | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CN119823996A (zh) * | 2019-08-05 | 2025-04-15 | 森特萨制药(英国)有限公司 | 抗bdca-2抗体 |
| PE20231678A1 (es) * | 2020-12-03 | 2023-10-19 | Biogen Ma Inc | Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico |
| MX2023007133A (es) | 2020-12-17 | 2023-06-27 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos. |
| CN113484512B (zh) * | 2021-06-01 | 2023-06-27 | 中国农业科学院油料作物研究所 | 黄曲霉毒素风险预警智能感知卡及其应用 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| WO2024010118A1 (ko) * | 2022-07-07 | 2024-01-11 | 주식회사 유틸렉스 | 항 bdca-2 항체 및 이의 용도 |
| KR20250128365A (ko) | 2022-12-28 | 2025-08-27 | 듀얼리티 바이올로직스 (상하이) 컴퍼니 리미티드 | 항-bdca2 항체-약물 접합체 및 이의 용도 |
| TW202509070A (zh) * | 2023-05-10 | 2025-03-01 | 新加坡商創响私人有限公司 | Bdca2-標靶抗體及其用途 |
| CN119119267A (zh) * | 2023-06-12 | 2024-12-13 | 三生国健药业（上海）股份有限公司 | 抗bdca2抗体 |
| WO2025051083A1 (zh) * | 2023-09-05 | 2025-03-13 | 上海宏成药业有限公司 | 抗bdca-2特异性抗体及其用途 |
| WO2025091023A1 (en) * | 2023-10-27 | 2025-05-01 | Northwestern University | Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof |
| CN120098124A (zh) * | 2023-12-05 | 2025-06-06 | 苏州普乐康医药科技有限公司 | 一种抗bdca-2抗体及其制备方法和应用 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
| CN119591712B (zh) * | 2024-11-27 | 2025-11-21 | 纽迈生物科技(苏州)有限公司 | 靶向人类浆细胞样树突状细胞的单克隆抗体及其应用 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1026240A3 (en) | 1988-09-02 | 2004-04-07 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6201671B1 (en) | 1998-12-04 | 2001-03-13 | International Business Machines Corporation | Seed layer for a nickel oxide pinning layer for increasing the magnetoresistance of a spin valve sensor |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| DE60033062T2 (de) * | 1999-11-15 | 2007-08-23 | Miltenyi Biotec Gmbh | Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen |
| US7030228B1 (en) * | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| US20070148171A1 (en) | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| AU2003254019A1 (en) * | 2002-07-18 | 2004-02-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods to select dendritic cells from a heterogeneous cell population |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| NZ542316A (en) | 2003-02-14 | 2006-04-28 | Biogen Idec Inc | An expression cassette and vector for transient or stable expression of exogenous molecules |
| JP4667383B2 (ja) | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用 |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| JP2008500271A (ja) * | 2003-10-14 | 2008-01-10 | ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン | 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CA2566473A1 (en) * | 2004-05-17 | 2005-12-08 | Board Of Trustees Of The University Of Illinois | Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens |
| CA2573192C (en) | 2004-08-04 | 2013-09-10 | Applied Molecular Evolution Inc. | Variant fc regions |
| DK1919503T3 (en) | 2005-08-10 | 2014-12-15 | Macrogenics Inc | Identification and preparation of antibodies with variant fc regions and methods of use thereof |
| BRPI0807613A2 (pt) * | 2007-02-23 | 2014-06-10 | Baylor Res Inst | Ativação de antígeno humano presente em células através de clec-6 |
| US8282964B2 (en) * | 2007-10-27 | 2012-10-09 | Medical Diagnostic Laboratories, Llc | Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda |
| WO2009135181A2 (en) | 2008-05-02 | 2009-11-05 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| EP2361263A1 (en) * | 2008-10-31 | 2011-08-31 | Abbott Biotherapeutics Corp. | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗ｃｄｃｐ１抗體 |
| FR2968561B1 (fr) * | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
-
2013
- 2013-12-10 PT PT138143409T patent/PT2928923T/pt unknown
- 2013-12-10 PL PL13814340T patent/PL2928923T3/pl unknown
- 2013-12-10 DK DK13814340.9T patent/DK2928923T3/da active
- 2013-12-10 NZ NZ708033A patent/NZ708033A/en active IP Right Revival
- 2013-12-10 RS RS20200365A patent/RS60084B1/sr unknown
- 2013-12-10 EA EA201591113A patent/EA034757B1/ru unknown
- 2013-12-10 WO PCT/US2013/074208 patent/WO2014093396A1/en not_active Ceased
- 2013-12-10 KR KR1020157017299A patent/KR20150094658A/ko not_active Withdrawn
- 2013-12-10 CN CN201380071162.8A patent/CN105452295B/zh active Active
- 2013-12-10 EP EP19209959.6A patent/EP3686218A1/en active Pending
- 2013-12-10 HU HUE13814340A patent/HUE047874T2/hu unknown
- 2013-12-10 JP JP2015545935A patent/JP6490591B2/ja active Active
- 2013-12-10 AU AU2013359419A patent/AU2013359419B2/en active Active
- 2013-12-10 HR HRP20200174TT patent/HRP20200174T1/hr unknown
- 2013-12-10 CA CA2893375A patent/CA2893375A1/en active Pending
- 2013-12-10 ES ES13814340T patent/ES2780398T3/es active Active
- 2013-12-10 US US14/649,297 patent/US9902775B2/en active Active
- 2013-12-10 KR KR1020207031486A patent/KR102344907B1/ko active Active
- 2013-12-10 EP EP13814340.9A patent/EP2928923B1/en active Active
- 2013-12-10 LT LTEP13814340.9T patent/LT2928923T/lt unknown
- 2013-12-10 SI SI201331663T patent/SI2928923T1/sl unknown
- 2013-12-10 CN CN202010418430.0A patent/CN111961134B/zh active Active
- 2013-12-10 BR BR122020023058-4A patent/BR122020023058B1/pt active IP Right Grant
- 2013-12-10 SM SM20200193T patent/SMT202000193T1/it unknown
- 2013-12-10 MX MX2015007034A patent/MX363407B/es unknown
-
2015
- 2015-05-13 IL IL238804A patent/IL238804B/en unknown
- 2015-05-29 ZA ZA2015/03881A patent/ZA201503881B/en unknown
-
2018
- 2018-01-12 US US15/869,514 patent/US20180362652A1/en not_active Abandoned
-
2019
- 2019-02-27 JP JP2019034198A patent/JP6889741B2/ja active Active
-
2020
- 2020-03-19 CY CY20201100263T patent/CY1122956T1/el unknown
-
2021
- 2021-05-21 JP JP2021086053A patent/JP2021130677A/ja active Pending
- 2021-08-09 IL IL285475A patent/IL285475A/en unknown
-
2024
- 2024-01-18 JP JP2024006009A patent/JP2024045253A/ja active Pending
-
2025
- 2025-01-27 US US19/037,765 patent/US20250304700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505556A5 (enExample) | ||
| EP3668898B1 (en) | Humanized antibodies for cd3 | |
| US11352432B2 (en) | Antibodies specifically binding to human IL-1R7 | |
| JP2015533853A5 (enExample) | ||
| JP2018519364A5 (enExample) | ||
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2012526558A5 (enExample) | ||
| JP2013545738A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2010526028A5 (enExample) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2020523038A5 (enExample) | ||
| WO2021226591A1 (en) | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof | |
| JP2015509960A5 (enExample) | ||
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| JP2013519690A5 (enExample) | ||
| JP7604401B2 (ja) | 抗体および使用方法 | |
| JP7698635B2 (ja) | 抗幹細胞因子抗体及びその使用方法 | |
| EP4392063A1 (en) | Antibodies targeting immunosuppressive b cells | |
| JP2018529672A5 (enExample) | ||
| WO2023028159A1 (en) | Methods of treating cancers associated with immunosuppressive b cells | |
| JP2019518473A5 (enExample) | ||
| US20220204644A1 (en) | Combination of her2 antibodies |